CN103787969A - 一种(1s)-1-苯基-3,4-二氢-2(1h)-异喹啉甲酸酯的制备方法 - Google Patents
一种(1s)-1-苯基-3,4-二氢-2(1h)-异喹啉甲酸酯的制备方法 Download PDFInfo
- Publication number
- CN103787969A CN103787969A CN201210425678.5A CN201210425678A CN103787969A CN 103787969 A CN103787969 A CN 103787969A CN 201210425678 A CN201210425678 A CN 201210425678A CN 103787969 A CN103787969 A CN 103787969A
- Authority
- CN
- China
- Prior art keywords
- formula
- dihydro
- phenyl
- isoquinoline
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims abstract description 64
- 238000006243 chemical reaction Methods 0.000 claims abstract description 33
- 239000001569 carbon dioxide Substances 0.000 claims abstract description 22
- 229910002092 carbon dioxide Inorganic materials 0.000 claims abstract description 22
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 10
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 9
- 239000003960 organic solvent Substances 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims description 23
- 235000011089 carbon dioxide Nutrition 0.000 claims description 19
- 150000001875 compounds Chemical class 0.000 claims description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 12
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- 239000003513 alkali Substances 0.000 claims description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 6
- 230000002152 alkylating effect Effects 0.000 claims description 5
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 5
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 4
- 235000015320 potassium carbonate Nutrition 0.000 claims description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 3
- 229910052806 inorganic carbonate Inorganic materials 0.000 claims description 3
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 claims description 3
- 230000035484 reaction time Effects 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 239000002798 polar solvent Substances 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 2
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 claims 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 abstract description 7
- 239000012535 impurity Substances 0.000 abstract description 5
- 230000007613 environmental effect Effects 0.000 abstract description 3
- 230000029936 alkylation Effects 0.000 abstract description 2
- 238000005804 alkylation reaction Methods 0.000 abstract description 2
- 238000009776 industrial production Methods 0.000 abstract description 2
- 239000003054 catalyst Substances 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- 239000012044 organic layer Substances 0.000 description 13
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- FBOUYBDGKBSUES-VXKWHMMOSA-N solifenacin Chemical compound C1([C@H]2C3=CC=CC=C3CCN2C(O[C@@H]2C3CCN(CC3)C2)=O)=CC=CC=C1 FBOUYBDGKBSUES-VXKWHMMOSA-N 0.000 description 12
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 11
- 239000012043 crude product Substances 0.000 description 11
- 238000001035 drying Methods 0.000 description 11
- 229960003855 solifenacin Drugs 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 239000000047 product Substances 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- -1 formic acid ester compound Chemical class 0.000 description 9
- 238000002390 rotary evaporation Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- CXHHBNMLPJOKQD-UHFFFAOYSA-M methyl carbonate Chemical compound COC([O-])=O CXHHBNMLPJOKQD-UHFFFAOYSA-M 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 206010020853 Hypertonic bladder Diseases 0.000 description 2
- ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 description 2
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 2
- NMJJFJNHVMGPGM-UHFFFAOYSA-N butyl formate Chemical compound CCCCOC=O NMJJFJNHVMGPGM-UHFFFAOYSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000007096 poisonous effect Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- FSNYTEYOTCTPSO-SSDOTTSWSA-N (2r)-1-azabicyclo[2.2.2]octan-2-ol Chemical compound C1CN2[C@H](O)CC1CC2 FSNYTEYOTCTPSO-SSDOTTSWSA-N 0.000 description 1
- IOEPOEDBBPRAEI-UHFFFAOYSA-N 1,2-dihydroisoquinoline Chemical compound C1=CC=C2CNC=CC2=C1 IOEPOEDBBPRAEI-UHFFFAOYSA-N 0.000 description 1
- MPPPKRYCTPRNTB-UHFFFAOYSA-N 1-bromobutane Chemical class CCCCBr MPPPKRYCTPRNTB-UHFFFAOYSA-N 0.000 description 1
- IVLICPVPXWEGCA-UHFFFAOYSA-N 3-quinuclidinol Chemical compound C1C[C@@H]2C(O)C[N@]1CC2 IVLICPVPXWEGCA-UHFFFAOYSA-N 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 102000017925 CHRM3 Human genes 0.000 description 1
- 101150060249 CHRM3 gene Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010063057 Cystitis noninfective Diseases 0.000 description 1
- UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 description 1
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 description 1
- 206010029279 Neurogenic bladder Diseases 0.000 description 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 description 1
- KFNNIILCVOLYIR-UHFFFAOYSA-N Propyl formate Chemical class CCCOC=O KFNNIILCVOLYIR-UHFFFAOYSA-N 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000006315 carbonylation Effects 0.000 description 1
- 238000005810 carbonylation reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000023819 chronic asthma Diseases 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 201000003139 chronic cystitis Diseases 0.000 description 1
- 201000009151 chronic rhinitis Diseases 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 206010029446 nocturia Diseases 0.000 description 1
- 208000020629 overactive bladder Diseases 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 239000012450 pharmaceutical intermediate Substances 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 231100000004 severe toxicity Toxicity 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- QJDRFICTELBSSO-UHFFFAOYSA-N triazol-4-ylidenemethanone Chemical compound O=C=C1C=NN=N1 QJDRFICTELBSSO-UHFFFAOYSA-N 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Abstract
Description
Claims (10)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210425678.5A CN103787969B (zh) | 2012-10-30 | 2012-10-30 | 一种(1s)-1-苯基-3,4-二氢-2(1h)-异喹啉甲酸酯的制备方法 |
PCT/CN2013/000067 WO2014067219A1 (zh) | 2012-10-30 | 2013-01-21 | 一种(1s)-1-苯基-3,4-二氢-2(1h)-异喹啉甲酸酯的制备方法 |
US14/690,282 US9399624B2 (en) | 2012-10-30 | 2015-04-17 | Process for preparing (1S)-1-phenyl-3,4-dihydro-2(1H)-isoquinoline-carboxylate |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210425678.5A CN103787969B (zh) | 2012-10-30 | 2012-10-30 | 一种(1s)-1-苯基-3,4-二氢-2(1h)-异喹啉甲酸酯的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103787969A true CN103787969A (zh) | 2014-05-14 |
CN103787969B CN103787969B (zh) | 2016-07-06 |
Family
ID=50626383
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210425678.5A Active CN103787969B (zh) | 2012-10-30 | 2012-10-30 | 一种(1s)-1-苯基-3,4-二氢-2(1h)-异喹啉甲酸酯的制备方法 |
Country Status (3)
Country | Link |
---|---|
US (1) | US9399624B2 (zh) |
CN (1) | CN103787969B (zh) |
WO (1) | WO2014067219A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107868085A (zh) * | 2017-11-23 | 2018-04-03 | 中山奕安泰医药科技有限公司 | 一种高纯度索非那新的精制制备工艺 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1300730A (zh) * | 2000-11-24 | 2001-06-27 | 中国科学院上海有机化学研究所 | 用co2代替剧毒的光气制备氨基甲酸酯类化合物的方法 |
US6566533B1 (en) * | 1999-03-25 | 2003-05-20 | Warner-Lambert Company Llc | Method of producing heterocylic carbamates from aza-heterocyclic compounds and carbon dioxide |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO2005012I1 (no) | 1994-12-28 | 2005-06-06 | Debio Rech Pharma Sa | Triptorelin og farmasoytisk akseptable salter derav |
EP1334084A4 (en) * | 2000-10-25 | 2005-11-02 | Pharmacia & Upjohn Co Llc | PROCESS FOR PREPARING CARBAMATES WITHOUT PHOSGENE |
CA2558877A1 (en) | 2004-02-09 | 2005-08-18 | Astellas Pharma Inc. | Solifenacin succinate-containing composition |
JPWO2005087231A1 (ja) | 2004-03-16 | 2008-01-24 | アステラス製薬株式会社 | ソリフェナシン含有組成物 |
CN1300730C (zh) | 2004-10-14 | 2007-02-14 | 上海交通大学 | 应用定向搜索的后向粗糙集属性约简方法 |
US20070173528A1 (en) | 2005-12-21 | 2007-07-26 | Nurit Perlman | Process for preparing solifenacin |
WO2008011462A2 (en) | 2006-07-19 | 2008-01-24 | Dr. Reddy's Laboratories Ltd. | Process for preparing solifenacin and its salts |
US20080114029A1 (en) | 2006-08-03 | 2008-05-15 | Tamas Koltai | Polymorphs of solifenacin intermediate |
CA2670365A1 (en) | 2006-11-22 | 2008-05-29 | Medichem S.A. | An improved process for the synthesis of solifenacin |
AR066206A1 (es) | 2007-03-30 | 2009-08-05 | Medichem Sa | Proceso para la sintesis de solifenacina |
WO2010103529A1 (en) | 2009-03-09 | 2010-09-16 | Megafine Pharma(P) Ltd. | A new method for the preparation of solifenacin and new intermediate thereof |
-
2012
- 2012-10-30 CN CN201210425678.5A patent/CN103787969B/zh active Active
-
2013
- 2013-01-21 WO PCT/CN2013/000067 patent/WO2014067219A1/zh active Application Filing
-
2015
- 2015-04-17 US US14/690,282 patent/US9399624B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6566533B1 (en) * | 1999-03-25 | 2003-05-20 | Warner-Lambert Company Llc | Method of producing heterocylic carbamates from aza-heterocyclic compounds and carbon dioxide |
CN1300730A (zh) * | 2000-11-24 | 2001-06-27 | 中国科学院上海有机化学研究所 | 用co2代替剧毒的光气制备氨基甲酸酯类化合物的方法 |
Non-Patent Citations (3)
Title |
---|
KEN J.BUTCHER: "Carbamate esters:a simple,mild method of formation", 《SYNLETT》, 30 October 1994 (1994-10-30), pages 825 - 826, XP002144444 * |
SCOTT L.PETERSON ET AL.: "Parallel Synthesis of Ureas and Carbamates from Amines and CO2 under Mild Conditions", 《ORGANIC LETTERS》, vol. 12, no. 6, 22 February 2010 (2010-02-22), pages 1340 - 1343, XP055014791, DOI: 10.1021/ol100259j * |
李立清等: "一锅法有效合成氨基甲酸酯类化合物", 《有机化学》, vol. 27, no. 4, 31 December 2007 (2007-12-31), pages 519 - 523 * |
Also Published As
Publication number | Publication date |
---|---|
WO2014067219A1 (zh) | 2014-05-08 |
CN103787969B (zh) | 2016-07-06 |
US9399624B2 (en) | 2016-07-26 |
US20150225348A1 (en) | 2015-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2698245C (en) | Process and intermediates for preparing integrase inhibitors | |
EP3712130B1 (en) | Method for synthesis of roxadustat and intermediate compounds thereof | |
CN101570550B (zh) | 手性二茂铁类双膦配体的合成方法 | |
CN105541844B (zh) | 一种高纯度利拉利汀的简易制备方法 | |
CN107011404B (zh) | 一种以胆酸为原料合成石胆酸的方法 | |
KR20150040340A (ko) | 인테그라아제 저해제 제조를 위한 방법 및 중간체 | |
CN105294426B (zh) | 氮杂环丁酮化合物制备方法及其中间体 | |
CN102850325A (zh) | 一种达比加群酯关键中间体的制备方法 | |
CN103059090A (zh) | 醋酸阿比特龙草酸盐以及醋酸阿比特龙的纯化方法 | |
CN105175346B (zh) | 一种合成瑞舒伐他汀钙中间体的方法 | |
CN110305018A (zh) | 一种3-溴-2-氟硝基苯的制备方法 | |
CN104628679A (zh) | Bitopertin的新合成方法及其中间体 | |
CN108623455A (zh) | 一种抗心衰药物的中间体 | |
CN103787969A (zh) | 一种(1s)-1-苯基-3,4-二氢-2(1h)-异喹啉甲酸酯的制备方法 | |
CN103113290A (zh) | 一种巴洛沙星中间体的制备方法 | |
CN106543081B (zh) | 一种1-二氟烷基异喹啉的制备方法 | |
CN105566260A (zh) | 一种呋塞米的制备方法 | |
CN103539728A (zh) | 一种拉唑类药物中间体氯甲基吡啶衍生物的合成方法 | |
CN111100042B (zh) | 一种2-甲氧基-5-磺酰胺基苯甲酸的制备方法 | |
CN105461617A (zh) | 4-[4-(三氟甲氧基)苯氧基]哌啶的制备方法 | |
CN106946724A (zh) | 单胺基抑制剂类中间体2‑乙酰氨基‑2‑苄基丙二酸单乙酯的合成方法 | |
WO2021242807A1 (en) | Methods for preparing methyl (s)-2-amino-3-(4-(2,3-dimethylpyridin-4-yl)phenyl)propionate and hydrochloric acid salts thereof | |
CN101781288B (zh) | 一种普仑司特中间体的制备方法 | |
KR20120087900A (ko) | 몬테루카스트 나트륨 중간체의 합성 방법 | |
CN104098556A (zh) | 一种新的利伐沙班的合成工艺 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address |
Address after: No. 306 Libing Road, Zhangjiang High tech Park, Pudong New Area, Shanghai, October 2012 Patentee after: SHANGHAI JINGXIN BIOLOGICAL MEDICAL Co.,Ltd. Country or region after: China Patentee after: Shaoxing Jingxin Pharmaceutical Co.,Ltd. Address before: No. 306 Libing Road, Zhangjiang High tech Park, Pudong New Area, Shanghai, October 2012 Patentee before: SHANGHAI JINGXIN BIOLOGICAL MEDICAL Co.,Ltd. Country or region before: China Patentee before: SHANGYU JINGXIN PHARMACEUTICAL Co.,Ltd. |
|
CP03 | Change of name, title or address |